<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04667598</url>
  </required_header>
  <id_info>
    <org_study_id>JWWX-2020</org_study_id>
    <nct_id>NCT04667598</nct_id>
  </id_info>
  <brief_title>Clinical and Metabonomics Study on the Treatment of Heart Failure After Myocardial Infarction With Modified Wenxin Decoction</brief_title>
  <official_title>Clinical and Metabonomics Study on the Treatment of Heart Failure After Myocardial Infarction With Modified Wenxin Decoction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jun Li</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To elucidate the efficacy and safety of weixin decoction in the treatment of heart failure&#xD;
      after myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To elucidate the long-term protective effect of flavored Wenxin Decoction on heart failure&#xD;
      after myocardial infarction.&#xD;
&#xD;
      To elucidate the effective components in the treatment of heart failure and the mechanism of&#xD;
      metabolism regulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major cardiovascular events</measure>
    <time_frame>One months after drug intervention</time_frame>
    <description>Rates of cardiac death, acute myocardial infarction, stroke, and heart failure readmission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary indicators</measure>
    <time_frame>Into the group day 1, week 4, week 8, week 12</time_frame>
    <description>NT-proBNP， six-minute walking experiment and echocardiographic</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Failure</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given modified Wenxin Tang granules, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>On the basis of basic western medicine treatment (secondary prevention of coronary heart disease + anti-heart failure treatment), Patients in this group will be given placebo, one dose per day, administered in two doses, 150-200 mL each time, for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modified Wenxin Decoction</intervention_name>
    <description>Mainly including make aconite , astragalus ， Cassia twig , dried ginger , red peony root , Chuanxiong , Codonopsis codonopsis , Ophiopogon ophiopogon , Schisandra , Stamen , Asarum , licorice.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18-75 years old；&#xD;
&#xD;
          -  A history of acute myocardial infarction；&#xD;
&#xD;
          -  Cardiac function Ⅱ - Ⅲ level；&#xD;
&#xD;
          -  LVEF 50% or less;&#xD;
&#xD;
          -  Nt-probnp level ≥ 450 pg/ mL；&#xD;
&#xD;
          -  All men and women can sign the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coronary artery bypass grafting was performed within 12 weeks；&#xD;
&#xD;
          -  Undergo or possibly undergo cardiac resynchronization therapy;&#xD;
&#xD;
          -  Primary valvular disease, left ventricular outflow tract obstruction, myocarditis,&#xD;
             aneurysm, uncontrolled severe arrhythmia, cardiogenic shock, unstable angina pectoris,&#xD;
             or acute myocardial infarction;&#xD;
&#xD;
          -  Having a serious primary liver, kidney or blood system disease or having a serious&#xD;
             mental illness or a systemic disease that is out of control;&#xD;
&#xD;
          -  Serum creatinine &gt; 194.5 mol/L or serum potassium &gt; 5.5mmol /L;&#xD;
&#xD;
          -  The level of alanine aminotransferase or alkaline phosphatase is 1.5 times of the&#xD;
             normal upper limit of &gt;;&#xD;
&#xD;
          -  Abnormal blood pressure control, systolic blood pressure exceeding 180mmHg or&#xD;
             diastolic blood pressure exceeding 110mmHg;&#xD;
&#xD;
          -  Pregnancy or lactation; Known or suspected allergy to research drugs; To receive&#xD;
             another investigational drug within 30 days of randomization or to be unwilling or&#xD;
             unable to provide written consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Li, MD</last_name>
    <role>Study Director</role>
    <affiliation>Guang 'anmen Hospital of China Academy of Chinese Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jun Li, MD</last_name>
    <phone>13051458913</phone>
    <email>gamyylj@163.com</email>
  </overall_contact>
  <results_reference>
    <citation>Benjamin EJ, Virani SS, Callaway CW, Chamberlain AM, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD, Ferguson JF, Fornage M, Gillespie C, Isasi CR, Jiménez MC, Jordan LC, Judd SE, Lackland D, Lichtman JH, Lisabeth L, Liu S, Longenecker CT, Lutsey PL, Mackey JS, Matchar DB, Matsushita K, Mussolino ME, Nasir K, O'Flaherty M, Palaniappan LP, Pandey A, Pandey DK, Reeves MJ, Ritchey MD, Rodriguez CJ, Roth GA, Rosamond WD, Sampson UKA, Satou GM, Shah SH, Spartano NL, Tirschwell DL, Tsao CW, Voeks JH, Willey JZ, Wilkins JT, Wu JH, Alger HM, Wong SS, Muntner P; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018 Mar 20;137(12):e67-e492. doi: 10.1161/CIR.0000000000000558. Epub 2018 Jan 31. Review. Erratum in: Circulation. 2018 Mar 20;137(12 ):e493.</citation>
    <PMID>29386200</PMID>
  </results_reference>
  <results_reference>
    <citation>Hildebrandt P. Systolic and nonsystolic heart failure: equally serious threats. JAMA. 2006 Nov 8;296(18):2259-60.</citation>
    <PMID>17090774</PMID>
  </results_reference>
  <results_reference>
    <citation>Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998 Jan 27;97(3):282-9. Review.</citation>
    <PMID>9462531</PMID>
  </results_reference>
  <results_reference>
    <citation>Gerber Y, Melton LJ 3rd, Weston SA, Roger VL. Association between myocardial infarction and fractures: an emerging phenomenon. Circulation. 2011 Jul 19;124(3):297-303. doi: 10.1161/CIRCULATIONAHA.110.007195. Epub 2011 Jun 27.</citation>
    <PMID>21709062</PMID>
  </results_reference>
  <results_reference>
    <citation>Ezekowitz JA, Kaul P, Bakal JA, Armstrong PW, Welsh RC, McAlister FA. Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. J Am Coll Cardiol. 2009 Jan 6;53(1):13-20. doi: 10.1016/j.jacc.2008.08.067.</citation>
    <PMID>19118718</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 23, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guang'anmen Hospital of China Academy of Chinese Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jun Li</investigator_full_name>
    <investigator_title>Li Jun</investigator_title>
  </responsible_party>
  <keyword>Traditional Chinese Medicine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

